Virus Diseases
73 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Infections
Narrower: Adenoviridae Infections 1, Caliciviridae Infections 3, Chickenpox 8, Chikungunya Fever 1, Coronavirus Infections 10, Cytomegalovirus Infections 4, Dengue 1, Epstein-Barr Virus Infections 1, Hemorrhagic Fever, Ebola 6, Herpes Genitalis 3, Herpes Zoster 12, Influenza in Birds 1, Papillomavirus Infections 6, Rabies 3, Respiratory Syncytial Virus Infections 8, Rotavirus Infections 2, Zika Virus Infection 1
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 9vHPV Vaccine for papillomavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| abrysvo for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| abrysvo + Beyfortus for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ad26.ZEBOV + MVA-BN-Filo for hemorrhagic fever, ebola | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm D for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm D for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm F for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm F for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm H for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm H for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm J for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm J for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm L for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Adjuvant Dose Arm L for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen High Dose Arm A for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen High Dose Arm A for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen Low Dose Arm B for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Amezosvatein Antigen Low Dose Arm B for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ansuvimab for hemorrhagic fever, ebola | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Artesunate for cytomegalovirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Awake timed prone and repositioning for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Beyfortus for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biospecimen Collection + Nasal Swab + Survey Administration + REMDESIVIR for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| coadministration for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| COVID-19 vaccine for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVI-VZV-001 for chickenpox | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVI-VZV-001 for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| dexmedetomidine nasal spray group + long duration high voltage pulse RF therapy group for herpes zoster | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ervebo® booster for hemorrhagic fever, ebola | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluvoxamine for coronavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-dose experimental vaccine for herpes zoster | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hydroxychloroquine + azithromycin for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IFN-γ positive selected T-cells for adenoviridae infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IFN-γ positive selected T-cells for cytomegalovirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Immulina for virus diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inmazeb for hemorrhagic fever, ebola | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lb-dtk-mv for cytomegalovirus infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lb-dtk-mv for epstein-barr virus infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-dose experimental vaccine for herpes zoster | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for rotavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-1018-H5 for influenza in birds | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nirsevimab for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Oxygen-ozone therapy, probiotic supplementation and Standard of care + SivoMixx (200 billion) for coronavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (3 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| prone positioning for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Positioning (PP) for coronavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rabies vaccine for rabies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for herpes zoster | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| RECOMBINANT ZAIRE EBOLAVIRUS KIKWIT-95 ENVELOPE GLYCOPROTEIN MODIFIED VESICULAR STOMATITIS VIRUS for hemorrhagic fever, ebola | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RSVPreF3 OA investigational vaccine for respiratory syncytial virus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S-337395 for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tetanus-Diphtheria booster for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tradipitant for coronavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 high-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 low-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valganciclovir for cytomegalovirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Viral Specific T-cells (VSTs) for virus diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G1.1-NN for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VXA-G2.4-NS for caliciviridae infections | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wharton's jelly derived Mesenchymal stem cells. for coronavirus infections | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for chikungunya fever | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for dengue | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wolbachia-infected Aedes aegypti for zika virus infection | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zabdeno® booster for hemorrhagic fever, ebola | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zelicapavir for respiratory syncytial virus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.